EU marketing authorisation has been given to Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.
List view / Grid view
Filter the results
The EMA CHMP has revealed its suggestion to grant marketing authorisation to seven medicines after its most recent meeting.
The FDA has given the XWL-008 compound Orphan Drug Designation for the treatment of narcolepsy.